Parunoflast
Small molecule
Also known as VTX3232
Evidence outlook · lead readout
NCT06771115 · Obesity
The reported results come from study designs that frequently fail to replicate under controlled conditions; see the rationale below.
NCT06771115: Randomised, quadruple-blind, placebo-controlled Phase 2 (n=175) in obesity with cardiovascular risk factors. The primary endpoint was safety and tolerability, and it was met: adverse-event rates were similar to placebo. VTX3232 lowered hsCRP, but it did not reduce body weight alone or on top of semaglutide, so the study gives no evidence of efficacy on weight. Registry results were posted on 2026-09-29; the efficacy figures come from the sponsor's release. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06771115 NCT06771115 · Obesity Randomised, quadruple-blind, placebo-controlled Phase 2 (n=175) in obesity with cardiovascular risk factors. The primary endpoint was safety and tolerability, and it was met: adverse-event rates were similar to placebo. VTX3232 lowered hsCRP, but it did not reduce body weight alone or on top of semaglutide, so the study gives no evidence of efficacy on weight. Registry results were posted on 2026-09-29; the efficacy figures come from the sponsor's release. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06771115 | 2 | Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion (Day 1 of treatment period through study completion, up to 16 weeks) 2025-09-10 | Primary (safety): TEAE incidence placebo 49% vs VTX3232 46% (monotherapy arms); placebo+semaglutide 56% vs VTX3232+semaglutide 56%. Secondary: hsCRP -78% at week 12 with VTX3232 vs +3% with placebo (modified analysis set, p<0.0001). Weight: no weight loss with VTX3232 alone and no added weight loss over semaglutide (sponsor release). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
Other NLRP3 inflammasome drugs
ABP-745, Ruvonoflast, Selnoflast, AZD4144. Compare all 5 NLRP3 inflammasome drugs
Other NLRP3 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Parkinson's Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Parunoflast: this drug | Phase 2 | Small molecule | NLRP3 inflammasome, NLRP3 | Weak signal | Featured results are safety only in this race | |
| Amantadine ER (Gocovri / ADS-5102) | Approved | Small molecule | NMDA receptor | Reliable signal | NCT02274766: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): ADS-5102 (Amantadine HCl Extended Release) -20.7 units on a scale (Standard Error 2.2) vs Placebo -6.3 units on a scale (Standard Error 2.08) NCT02136914: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 (Baseline to Week 12): ADS-5102 (340 mg) -15.9 units on a scale (Standard Error 1.62) vs Placebo -8 units on a scale (Standard Error 1.64) | |
| Apomorphine (Apokyn) | Approved | Small molecule | Dopamine receptor (non-ergoline agonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Apomorphine (Onapgo) | Approved | Small molecule | Dopamine receptor (non-ergoline agonist) | Reliable signal | NCT02006121: Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16) | |
| Crexont (IPX203) | Approved | Small molecule | dopamine precursor | Reliable signal | NCT03670953: Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) | |
| Entacapone (Comtess) | Approved | Small molecule | COMT | not yet graded | No reviewed efficacy summary in this indication | |
| Foslevodopa / Foscarbidopa (Vyalev) | Approved | Small molecule | dopamine precursor | Reliable signal | NCT04380142: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) | |
| Istradefylline (Nourianz) | Approved | Small molecule | adenosine A2A | Partial signal | NCT00199407: Placebo-corrected reduction in daily OFF time at endpoint: 4.6% (equivalent to 0.7 hours), P=0.03, favoring istradefylline 20mg/day over placebo. NCT01968031: Change from baseline in daily OFF time at week 12, istradefylline 20 mg and 40 mg vs placebo: no statistically significant difference for either dose (Kyowa Hakko Kirin topline release, 13 Dec 2016; no effect estimate published in the release). missed | |
| Levodopa (Inbrija) | Approved | Small molecule | dopamine precursor | Partial signal | NCT02240030: UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019) | |
| Levodopa-Carbidopa Intestinal Gel (Duopa) | Approved | Small molecule | dopamine precursor | Weak signal | NCT00357994: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) | |
| Opicapone (Ongentys) | Approved | Small molecule | COMT | Partial signal | NCT04978597: Change in MDS-UPDRS Part III total score from baseline to Week 24: -6.5 opicapone vs -4.3 placebo; difference -2.2 (95% CI -3.9, -0.5) favoring opicapone, p=0.010 NCT01568073: Change in absolute OFF-time vs placebo: opicapone 50 mg -60.8 min (95% CI -97.2 to -24.4), p=0.0015, and non-inferior to entacapone (-26.2 min, p=0.0051); opicapone 5 mg p=0.056 and 25 mg p=0.080 vs placebo (BIPARK-1, Lancet Neurol 2016). | |
| Parcopa | ApprovedUS marketing discontinued | Small molecule | dopamine precursor | Partial signal | NCT00139880: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively) NCT00139867: Patient preference: 45% preferred Parcopa (carbidopa-levodopa orally disintegrating tablets), 35% had no preference, 20% preferred conventional carbidopa-levodopa tablets. | |
| Pramipexole ER (Mirapex ER) | Approved | Small molecule | Dopamine D2 / D3 receptors | Reliable signal | NCT00466167: UPDRS II+III score change at week 18 (adjusted mean, points): extended release -11.0, immediate release -12.8, placebo -6.1; ER vs placebo p=0.0001, IR vs placebo p<0.0001. The registry labels the unit 'percentage of change from baseline'; the publication reports score changes from baseline means of 40.0 to 41.7. NCT00479401: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score (baseline and after 33 weeks treatment): Pramipexole Extended Release (PPX ER) -8.6 units on a scale (95% CI -9.9 to -7.2) vs Pramipexole Immediate Release (PPX IR) -8.8 units on a scale (95% CI -10.2 to -7.4) vs Placebo -3.8 units on a scale (95% CI -5.9 to -1.8) | |
| Rasagiline (Azilect) | Approved | Small molecule | MAO-B | Reliable signal | NCT01479530: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16) NCT01268891: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 6, 10, 14, and 18): Azilect® -1.59 hours (Standard Error 0.25) vs Placebo -1.24 hours (Standard Error 0.26) missed | |
| Rotigotine (Neupro) | Approved | Small molecule | Dopamine receptors | Weak signal | NCT01628926: UPDRS Part III change at 16 weeks, rotigotine vs placebo: -6.4 ± 1.2 (95% CI -8.7 to -4.1; p<0.001); non-inferior to ropinirole (n=420). NCT00244387: Absolute change in off-time vs baseline: rotigotine -2.5h, pramipexole -2.8h, placebo -0.9h; vs placebo: rotigotine -1.58h (95% CI -2.27 to -0.90, p<0.0001), pramipexole -1.94h (95% CI -2.63 to -1.25, p<0.0001); responder rate (>=30% off-time reduction): rotigotine 59.7%, pramipexole 67%, placebo 35% | |
| Rytary (IPX066) | Approved | Small molecule | dopamine precursor | Reliable signal | NCT00974974: Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) NCT00880620: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30 (Week 30): IPX066 145mg LD -11.7 units on a scale (Standard Deviation 10.97) | IPX066 245 mg LD -12.9 units on a scale (Standard Deviation 11.42) | IPX066 390 mg LD -14.9 units on a scale (Standard Deviation 11.85) vs Placebo -0.6 units on a scale (Standard Deviation 10.37) | |
| Safinamide (Xadago) | Approved | Small molecule | MAO-B | Partial signal | NCT03881371: Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543) NCT00605683: Primary endpoint (UPDRS III change, baseline to week 24), full ITT population (n=679): safinamide 100mg/d vs placebo borderline, P=0.073 (not met). In the pre-specified DA-monotherapy subgroup (n=666): safinamide 100mg/d significantly improved UPDRS III vs placebo, P=0.0396. | |
| Tavapadon (Juvmo) | Approved | Small molecule | D1/D5 | Reliable signal | NCT04223193: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score (Week 26): Tavapadon -10.3 score on a scale (Standard Error 0.99) vs Placebo -1.2 score on a scale (Standard Error 0.89) NCT04201093: Change From Baseline in the MDS-UPDRS Parts II and III Combined Score (Week 26): Tavapadon 5 mg -9.7 score on a scale (Standard Error 0.86) | Tavapadon 15 mg -10.2 score on a scale (Standard Error 0.88) vs Placebo 1.8 score on a scale (Standard Error 0.82) | |
| Pramipexole (Sifrol/Mirapex) | US approval withdrawn | Small molecule | Dopamine D2/D3 receptors | Partial signal | NCT02177357: UPDRS Part II, Part III and Parts II+III combined: pramipexole significantly more effective than placebo at 15 weeks | |
| Ambroxol | Phase 3 | Small molecule | GBA1/glucocerebrosidase | Partial signal | NCT05287503: Primary (MoCA change at 52 weeks): -0·69 ambroxol vs 0·19 placebo (n=28 per group); mean difference -1·18 (95%CI -2·63 to 0·27, p=0·053); adjusted mean difference -1·05 (95%CI -2·17 to -0·06, p=0·030), significantly worse with ambroxol. missed | |
| Bemdaneprocel (MSK-DA01) | Phase 3 | Cell therapy | Midbrain dopaminergic neurons | Weak signal | Featured results are safety only in this race | |
| BIIB122 / DNL151 (LRRK2 Inhibitor) | Phase 3 | Small molecule | LRRK2 | Weak signal | NCT05348785: Phase 2b LUMA (n=648, randomized, placebo-controlled) did not slow confirmed clinical worsening; Biogen and Denali said in May 2026 that they would discontinue BIIB122/DNL151 development in idiopathic Parkinson's disease. Denali continues the Phase 2a BEACON study in LRRK2-variant carriers. missed | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | Partial signal | NCT05357989: Primary MDS-UPDRS Part II change at month 6: 0.57 (10 mg) vs -0.10 (placebo); -0.04 (20 mg) vs -0.10 (placebo). missed | |
| Droxidopa (Northera) | Phase 3 | Small molecule | norepinephrine precursor | Partial signal | No reviewed efficacy summary in this indication | |
| HRG2010 | Phase 3 | Small molecule | Central dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide) | Partial signal | NCT06596876: Primary endpoint, change from baseline in mean daily 'off' time at the end of double-blind treatment: HRG2010 shortened 'off' time compared with sustained-release carbidopa/levodopa, per Hengrui; the key secondary (good 'on' time without troublesome dyskinesia) was also improved. The company disclosed no numbers. | |
| IncobotulinumtoxinA (Xeomin) | Phase 3 | Protein / enzyme therapeutic | acetylcholine release | not yet graded | NCT02091739: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 (Baseline and Week 4): MP: IncobotulinumtoxinA (Xeomin) (75 Units) -0.06 gram per minute (g/min) (Standard Error 0.027) | MP: IncobotulinumtoxinA (Xeomin) (100 Units) -0.13 gram per minute (g/min) (Standard Error 0.026) vs MP: Placebo -0.04 gram per minute (g/min) (Standard Error 0.033) phase 3 result · pivotal pending | |
| Levodopa / Carbidopa (ND0612) (Onerji) | Phase 3 | Small molecule | dopamine precursor | Partial signal | NCT02577523: Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) | |
| Piribedil (Clarium) | Phase 3 | Small molecule | D2/D3 | Partial signal | NCT01007864: Primary endpoint (median reaction time, TAP battery vigilance subtest, minutes 16-30, end of treatment): piribedil 996 ms vs comparator (pramipexole/ropinirole) 954 ms; P=0.68 - no significant difference. missed | |
| Pramipexole / Rasagiline (P2B001) | Phase 3 | Small molecule | dopamine / MAO-B | Reliable signal | NCT03329508: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160). (baseline to week 12): P2B001 -7.98 score on a scale (Standard Error 0.6) vs Rasagiline Capsule -4.69 score on a scale (Standard Error 0.61) vs Pramipexole Capsule -5.32 score on a scale (Standard Error 0.61) vs Pramipexole Extended Release -8.35 score on a scale (Standard Error 0.86) NCT01968460: Total UPDRS I, II, III Scores (Week 12): P2B001 Treatment A -5.97 units on a scale (Standard Error 0.94) | P2B001 Treatment B -5.15 units on a scale (Standard Error 0.9) vs Placebo -1.31 units on a scale (Standard Error 0.88) | |
| Prasinezumab | Phase 3 | Monoclonal antibody | alpha-synuclein | not yet graded | No reviewed efficacy summary in this indication | |
| Rotigotine (LY03003) (Jinyouping) | Phase 3 | Small molecule | Dopamine receptors | Partial signal | NCT04571164: Change from baseline in UPDRS Part II+III total score: LY03003 -11.8 vs placebo -5.6 (P<0.001) | |
| Solengepras (CVN424) | Phase 3 | Small molecule | GPR6 | Weak signal | Featured results are safety only in this race | |
| Trigel (Lecigon) | Phase 3 | Small molecule | COMT | Partial signal | Featured results are non-efficacy only in this race | |
| BHV-8000 | Phase 2/3 | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| VG081821AC | Phase 2/3 | Small molecule | adenosine A2A | not yet graded | No reviewed efficacy summary in this indication | |
| AAV-GAD Gene Therapy | Phase 2 | Gene therapy / editing | Glutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleus | Weak signal | NCT05603312: Treatment-related adverse events: 0/5 AAV-GAD low dose, 1/5 AAV-GAD high dose, and 0/4 sham surgery; treatment-related serious adverse events: 0/5, 0/5, and 0/4, respectively. | |
| ABP-745 | Phase 2(overall) | Small molecule | NLRP3 inflammasome | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AFFITOPE PD01A / ACI-7104.056 | Phase 2 | Vaccine | alpha-synuclein | not yet graded | No reviewed efficacy summary in this indication | |
| Ametefgene Parvec | Phase 2 | Gene therapy / editing | GDNF | Weak signal | Featured results are safety only in this race | |
| AP-472 | Phase 2 | Small molecule | mGlu4 | not yet graded | No reviewed efficacy summary in this indication | |
| Bezisterim | Phase 2 | Small molecule | ERK/NF-kB inflammatory | Partial signal | NCT05083260: Registered primary objectives were safety/drug-interaction; exploratory motor finding: NE3107 (bezisterim) + levodopa improved MDS-UPDRS Part 3 motor score >=3 points more than levodopa alone; roughly 6 points more in patients under age 70 | |
| Cannabidiol (Kanbis) | Phase 2 | Small molecule | cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| Carbidopa / Levodopa (WD-1603) | Phase 2 | Small molecule | dopamine precursor | Partial signal | NCT05036473: Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) | |
| CNM-Au8 | Phase 2 | Nanoparticle | mitochondrial energy metabolism | Weak signal | NCT03815916: NAD+/NADH ratio (primary endpoint) in the REPAIR-PD cohort (NCT03815916): +6.8% increase with CNM-Au8 (0.386 units), p=0.108 (paired t-test) — not statistically significant on its own; significance (p=0.037) was reached only in the prespecified integrated analysis combining the PD and MS (REPAIR-MS) cohorts together. missed | |
| CPL500036 | Phase 2 | Small molecule | PDE10A | Partial signal | NCT05297201: Change from baseline in total UDysRS score at Week 4 (LS mean difference vs placebo): 20 mg dose -12.30 units (p<0.001, Cohen's d 0.90); 40 mg dose -13.58 units (p<0.001, Cohen's d 1.00) | |
| ENERGI-F705 | Phase 2 | Small molecule | alpha-synuclein / mitochondrial ATP | not yet graded | No reviewed efficacy summary in this indication | |
| ENT-01 | Phase 2 | Small molecule | enteric neuron | Partial signal | NCT03781791: Weekly complete spontaneous bowel movements (CSBM): rose from 0.7 to 3.2 with ENT-01 vs 0.7 to 1.2 with placebo (P < 0.001), n=150 (Camilleri et al., Ann Intern Med 2022). | |
| Exenatide (PT320) | Phase 2 | Peptide | GLP-1 receptor | Partial signal | NCT04269642: Primary endpoint, mean change in MDS-UPDRS part 3 score: no statistical significance between test group 1 and the placebo group (p=0.7355); in test group 2 motor symptoms improved but again without statistical significance versus placebo (p=0.5042). missed | |
| Exidavnemab | Phase 2 | Monoclonal antibody | alpha-synuclein | Weak signal | No reviewed efficacy summary in this indication | |
| Glovadalen | Phase 2 | Small molecule | D1 receptor | Partial signal | NCT06055985: Change from baseline to Day 70 in average hours/day of OFF time (ATLANTIS trial, n=207, 1:1:1 low-dose/high-dose/placebo): low-dose UCB0022 (glovadalen) reduced OFF time by 0.8 hours/day vs placebo; high-dose reduced it by 0.45 hours/day vs placebo | |
| GT-02287 | Phase 2 | Small molecule | GBA1/glucocerebrosidase | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| KM-819 | Phase 2 | Small molecule | FAF1 | Weak signal | Featured results are safety only in this race | |
| Lenrispodun (ITI-214) | Phase 2 | Small molecule | PDE1 | Partial signal | No reviewed efficacy summary in this indication | |
| Lu AF28996 | Phase 2 | Small molecule | D1/D2 | Weak signal | No reviewed efficacy summary in this indication | |
| Matsupexole (KDT-3594) | Phase 2 | Small molecule | D2/D3 | Partial signal | No reviewed efficacy summary in this indication | |
| Mesdopetam (IRL790) | Phase 2 | Small molecule | D3 | Partial signal | NCT04435431: Primary endpoint, change in daily hours of good ON-time (ON-time without troublesome dyskinesia), mesdopetam vs placebo at 12 weeks: not statistically significant. Secondary endpoint UDysRS (ON-phase dyskinesia) improved at 7.5 mg bid (nominal p = 0.026). missed NCT03368170: Unified Dyskinesia Rating Scale (UDysRS) (Baseline and 4 weeks): Mesdopetam -4.2 score on a scale (95% CI -7.3 to -1) vs Placebo -7 score on a scale (95% CI -10.3 to -3.8) missed | |
| MT101-5 | Phase 2 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| NEU-411 | Phase 2 | Small molecule | LRRK2 | not yet graded | No reviewed efficacy summary in this indication | |
| NouvNeu001 | Phase 2 | Cell therapy | dopaminergic neuron replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Pirepemat (IRL752) | Phase 2 | Small molecule | 5-HT/norepinephrine | Partial signal | NCT05258071: Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment. (Baseline to end of full dose treatment (up to Day 84).): Pirepemat 300 mg 76.9 % of baseline fall rate (Standard Deviation 72.05) | Pirepemat 600 mg 64.5 % of baseline fall rate (Standard Deviation 49.18) vs Placebo 68.9 % of baseline fall rate (Standard Deviation 90.22) missed | |
| Pramipexole ER / Aprepitant (CTC-413) | Phase 2 | Combination | Dopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component) | Weak signal | No reviewed efficacy summary in this indication | |
| Selnoflast | Phase 2(overall) | Small molecule | NLRP3 inflammasome | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| AZD4144 | Phase 1(overall) | Small molecule | NLRP3 inflammasome | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| HL-400 | Phase 1 | Small molecule | NLRP3 | not yet graded | No reviewed efficacy summary in this indication | |
| VENT-02 | Discontinued | Small molecule | NLRP3 | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 65 furthest-along competitors are listed; 63 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.